header logo image

Stem Cell Agency Adds Fresh Details to IOM Response

January 27th, 2013 8:07 am

The California stem cell agency today
issued a press release touting “dramatic changes” at the agency in response to critical recommendations by the Institute of Medicine.

The press release contained a few more
details about the changes than were released in the Power Point
presentation yesterday. Here is the text of those details.
  • “The 13 Board members appointed from
    institutions eligible for funding from the stem cell agency, such as
    those in the University of California system, would no longer vote on
    any grants brought before the Board but would instead abstain
  • “All members of the Board would
    be able to participate in discussions on applications but only
    patient advocates and independent members of the Board would be able
    to vote on funding issues (members would continue to refrain from
    any discussion of specific applications from their institutions)
  • “Patient Advocates would
    continue to be members of the Grants Working Groups but would not
    vote on individual applications
  • “Programmatic review, aimed at
    balancing the agency’s portfolio, would take place at public Board
    meetings where members have a chance to make changes to
    recommendations from the Grants Working Group
  • “Industry involvement would
    increase, where appropriate, on the Grants Working Group, and also
    feature in a newly constituted Scientific Advisory Board; the
    structure and membership of this group is still under discussion
  • “Appeals on applications not
    recommended for funding will be handled by science staff who will
    evaluate them, determine if they merit further review by the Grants
    Working Group, and ultimately make recommendations to the Board.
    Staff will also be allowed to advocate for additional grants not
    recommended for funding by the Grants Working Group that they
    believe should be considered in programmatic review
  • “The Chair and President would
    share a division of responsibilities with the President supervising
    all scientific operations and internal operational responsibilities.
    In addition the Chief Financial Officer would report to the
    President. The Chair would handle the ‘external affairs’ aspect
    of the agency, things such as financial sustainability to raise
    additional funds, state legislative relations, bond financing,
    public communications etc.
  • “IOM recommendation on the
    creation of a Scientific Advisory Board to provide counsel on such
    issues as funding priorities and portfolio strategy will be
    implemented by staff
  • “IOM recommendations on
    Intellectual Property will be referred to the agency’s IP
    subcommittee which will review and report back to the full board
    with options and recommendations
  • “IOM recommendations on
    Sustainability: Chair, working with the President, will develop a
    plan to address this and present to the Board when ready

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/MHSytXHG-zU/stem-cell-agency-adds-fresh-details-to.html

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick